InMode Ltd. (NASDAQ:INMD) is highlighted as an undervalued medical device stock to consider buying. Analyst Caitlin Cronin from Canaccord Genuity maintained a Hold rating on INMD with a price target of $15.00.

The company revised its full-year guidance due to market uncertainty and weak economic outlook in the US.

For fiscal Q2 2025, InMode Ltd. (NASDAQ:INMD) expects a non-GAAP gross margin of 79%-80% and revenue between $95.4 million to $95.5 million.

Full-year revenue for 2025 is projected to be $365 million to $375 million, adjusting from the previous guidance of $395 million to $405 million.

InMode Ltd. (NASDAQ:INMD) specializes in developing minimally invasive aesthetic medical products for various procedures, including wrinkle reduction, hair removal, skin rejuvenation, cellulite treatment, and more.

Read more at Yahoo Finance: Canaccord Genuity Maintains a Hold Rating on InMode Ltd. (INMD)